Company intelligence / Profile preview

Bioconnect Systems, Inc.

Ambler, Pennsylvania, United Stateslungpacer.com ↗

Ownership: Private
Development stage: Phase 3

Overview

Bioconnect Systems has pioneered a new technique for performing microvascular surgery, with products that can improve quality of life for nearly 400,000 U.S. and 2 million worldwide patients suffering from End Stage Renal Disease.

Therapeutic areas: Nephrology
Modalities: Surgical implants
Industry: Implantable Medical Devices

Drug pipeline

1 asset

vonapanitase

Phase 3

Indications: Hemodialysis vascular access, Peripheral artery disease

Beyond the preview

Go deeper on Bioconnect Systems, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bioconnect Systems, Inc..

Explore the full profile